Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Standard treatment for patients with limited stage small cell lung cancer (LS SCLC) is concurrent platinum–etoposide chemotherapy and thoracic radiotherapy (TRT). Up to 30% of patients are cured, but severe toxicity is common, and we are not able to identify those who are cured or those who experience severe toxicity before chemoradiotherapy commences. Studies of other cancer patients show that low muscle mass and muscle radiodensity are associated with inferior survival and that a high drug dose per kilogram lean body mass (LBM) is associated with more toxicity, but this has not been investigated in LS SCLC. We analysed patients from a randomized trial comparing two schedules of TRT (<i>n </i> = 157) to investigate the prognostic and predictive role of these muscle measures in LS SCLC. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Patients from a trial comparing once daily hypofractionated with twice daily hyperfractionated TRT were analysed. The skeletal muscle index (SMI), skeletal muscle radiodensity (SMD), and LBM were assessed from baseline computed tomography scans at the L3 level using the SliceOMatic software.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Images at the L3 level were available for 122 patients (77.7%). Median age was 64 years, 18% had performance status 2, and 38% had stage III. Grade 3–4 toxicity was observed in 89%, and 5% died from treatment‐related side effects. Overall, the median overall survival was 23 months, and the 5 year survival was 25%. Median LBM was 45.2 (range: 16–65) kg, the median SMI 44.8 (range: 29–77) cm<sup>2</sup>/m<sup>2</sup>, and the median SMD 39.3 (range 16–62) HU. There were no significant associations between survival and any of the muscle measures in the univariable analyses (SMI: <i>P </i> = 0.906, SMD: <i>P </i> = 0.829) or in multivariable analyses adjusting for baseline characteristics (SMI: <i>P </i> = 0.836, SMD: <i>P </i> = 0.260). A higher cisplatin dose per kilogram LBM in the first course significantly increased the risk of grade 3–4 haematological toxicity (<i>P </i> = 0.011) and neutropenic infections (<i>P </i> = 0.012). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Patients who received a high dose of cisplatin per kilogram LBM had more haematological toxicity and neutropenic infections than other patients. None of the muscle measures were independent prognostic factors for survival in our cohort of LS SCLC patients who underwent standard chemoradiotherapy.</p></section>

Sociodemographic and clinical factors associated with low muscle mass and composition in people treated with (chemo)radiotherapy for lung cancer

Living with low muscle mass and its impact throughout curative treatment for lung cancer: A qualitative study

Impact of low skeletal muscle mass and density on outcomes of locally advanced esophageal cancer patients treated with radical radiotherapy.

Skeletal Muscle Depletion During Chemoradiotherapy and Radiomics Features As Prognostic Factors of Toxicity and Outcomes in Patients with Gastric Cancer

Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study

Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112

Progressive Skeletal Muscle Loss After Surgery and Adjuvant Radiotherapy Impact Survival Outcomes in Patients With Early Stage Cervical Cancer

Handgrip weakness, low fat‐free mass, and overall survival in non‐small cell lung cancer treated with curative‐intent radiotherapy

Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis

Skeletal muscle adaptations in patients with lung cancer: Longitudinal observations from the whole body to cellular level

Associations between muscle measures, survival, and toxicity in patients with limited stage small cell lung cancer

Is skeletal muscle loss associated with chemoradiotherapy toxicity in nasopharyngeal carcinoma patients? A prospective study

Skeletal muscle mass during chemotherapy for haematological malignancies: a retrospective study

Evaluation of nutritional parameters that may be associated with survival in patients with locally advanced non-small cell lung carcinoma receiving definitive concurrent chemoradiotherapy: retrospective study conducted in a tertiary pulmonary hospital

Prognostic Impact of Low Muscle Mass and Inflammatory Markers in Stage III Nonsmall Cell Lung Cancer Turkish Oncology Group and Turkish Society of Radiation Oncology Thoracic Cancer Study Group (08-005)

Quantitative Analysis of Skeletal Muscle Wasting During Chemoradiotherapy Predicts Toxicity and Survival Outcomes in Gastric Cancer Patients

The impact of low muscle mass and strength on chemotherapy toxicity in women with early breast cancer.

Impact of muscle volume loss on acute oral mucositis in patients undergoing concurrent chemoradiotherapy after oral cancer resection

The Prevalence of Sarcopenia and Relationships Between Dietary Intake and Muscle Mass in Head and Neck Cancer Patients Undergoing Radiotherapy: A Longitudinal Study.

Association between Skeletal Muscle Loss and the Response to Neoadjuvant Chemotherapy for Breast Cancer

Impact of low skeletal muscle mass in oropharyngeal cancer patients treated with radical chemo-radiotherapy: A mono-institutional experience